Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on Protara Therapeutics, with seven buy ratings and one sell rating among eight firms. The average 12-month price target is $26.25, well above the stock’s recent $3.82 price.
• Institutional investors have increased their exposure to TARA, including major purchases and stake increases by AIGH Capital, ADAR1 Capital, Janus Henderson and Integral Health. Hedge funds and other institutions collectively own 38.13% of the company.
• Protara reported a quarterly loss of $0.36 per share, missing the $0.33 consensus estimate, while analysts expect a full-year loss of $1.48 per share. The clinical-stage biotech is developing immunotherapies for virus-driven cancers, including its lead candidate PTX-35.

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $26.25.

TARA has been the topic of a number of research analyst reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Protara Therapeutics in a research report on Friday, July 17th. Cantor Fitzgerald restated an "overweight" rating on shares of Protara Therapeutics in a report on Wednesday, May 20th. JPMorgan Chase & Co. reduced their price objective on Protara Therapeutics from $27.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, May 14th. HC Wainwright reaffirmed a "buy" rating on shares of Protara Therapeutics in a report on Wednesday, May 20th. Finally, UBS Group reiterated a "buy" rating on shares of Protara Therapeutics in a research report on Wednesday, May 20th.

Institutional Investors Weigh In On Protara Therapeutics

Hedge funds have recently bought and sold shares of the business. AIGH Capital Management LLC purchased a new position in Protara Therapeutics during the 1st quarter worth $8,454,000. ADAR1 Capital Management LLC grew its position in shares of Protara Therapeutics by 3,127.4% during the 4th quarter. ADAR1 Capital Management LLC now owns 1,136,799 shares of the company's stock worth $6,059,000 after buying an additional 1,101,576 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new position in shares of Protara Therapeutics during the 4th quarter worth $5,562,000. Janus Henderson Group PLC increased its stake in shares of Protara Therapeutics by 21.5% during the fourth quarter. Janus Henderson Group PLC now owns 5,141,616 shares of the company's stock valued at $27,379,000 after buying an additional 910,285 shares during the period. Finally, Integral Health Asset Management LLC raised its holdings in shares of Protara Therapeutics by 60.7% in the fourth quarter. Integral Health Asset Management LLC now owns 2,250,000 shares of the company's stock worth $11,992,000 after buying an additional 850,000 shares during the last quarter. Hedge funds and other institutional investors own 38.13% of the company's stock.

Protara Therapeutics Stock Performance

Shares of NASDAQ TARA opened at $3.82 on Friday. The company has a market cap of $225.76 million, a P/E ratio of -2.83 and a beta of 1.50. Protara Therapeutics has a 52-week low of $3.02 and a 52-week high of $7.82. The firm's fifty day moving average is $4.02 and its two-hundred day moving average is $4.81.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.03). As a group, analysts forecast that Protara Therapeutics will post -1.48 EPS for the current fiscal year.

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company's primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body's immune response to target tumor cells. Protara's therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara's lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source